Companies
Syner-G BioPharma Group
confirmed via five separate published case studies on its own domain, covering CDMO-to-in-house cGMP manufacturing scale-up in cell therapy, end-to-end CMC enablement for a clinical-stage biotech, smart scale-up solutions, technology-transfer mobilization to a CDMO,…
- Country
- United States
CMC tech transfer
Coverage
| US | |
|---|---|
| consulting-strategy | ✓ |
Regulatorsfda
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bioprocess scale-up consulting | consulting-strategy | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.